203 related articles for article (PubMed ID: 30548997)
1. Cloning of carrier cells infected with oncolytic adenovirus driven by midkine promoter and biosafety studies.
Hamada K; Takagi S; Kuboshima H; Shimada H; Takagi K; Yasuoka T; Matsubara K; Sassa Y; Furuya T; Suzuki K; Uchide T; Mizutani T; Tani K; Itoh H; Sugiyama T
J Gene Med; 2019 Feb; 21(2-3):e3064. PubMed ID: 30548997
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for oral squamous cell carcinoma with IAI.3B promoter-driven oncolytic adenovirus-infected carrier cells.
Zhang T; Hamada K; Hyodo M; Itoh H; Tani K; Goda H; Nakashiro K; Hamakawa H
Oncol Rep; 2011 Mar; 25(3):795-802. PubMed ID: 21206983
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.
Takagi-Kimura M; Yamano T; Tagawa M; Kubo S
Cancer Gene Ther; 2014 Mar; 21(3):126-32. PubMed ID: 24577130
[TBL] [Abstract][Full Text] [Related]
5. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
6. Carrier cell-mediated cell lysis of squamous cell carcinoma cells by squamous cell carcinoma antigen 1 promoter-driven oncolytic adenovirus.
Hamada K; Zhang T; Desaki J; Nakashiro K; Itoh H; Tani K; Koyama Y; Hamakawa H
J Gene Med; 2010 Jun; 12(6):545-54. PubMed ID: 20527047
[TBL] [Abstract][Full Text] [Related]
7. Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors.
Yamamoto Y; Nagasato M; Rin Y; Henmi M; Ino Y; Yachida S; Ohki R; Hiraoka N; Tagawa M; Aoki K
Cancer Med; 2017 Oct; 6(10):2385-2397. PubMed ID: 28941156
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic effect of Midkine promoter-based conditionally replicating adenoviruses expressing EGFR siRNA in head and neck squamous cancer cell line T891.
Uehara N; Otsuki N; Kubo M; Kitamoto J; Kojima Y; Teshima M; Shinomiya H; Shirakawa T; Nibu KI
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1231. PubMed ID: 32671980
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions.
Yoon AR; Hong J; Kim M; Yun CO
Sci Rep; 2018 Feb; 8(1):2233. PubMed ID: 29396500
[TBL] [Abstract][Full Text] [Related]
11. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
12. Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.
Rein DT; Volkmer A; Bauerschmitz G; Beyer IM; Janni W; Fleisch MC; Welter AK; Bauerschlag D; Schöndorf T; Breidenbach M
J Cancer Res Clin Oncol; 2012 Apr; 138(4):603-10. PubMed ID: 22209976
[TBL] [Abstract][Full Text] [Related]
13. Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter.
Cheng PH; Rao XM; Duan X; Li XF; Egger ME; McMasters KM; Zhou HS
J Mol Med (Berl); 2015 Feb; 93(2):211-23. PubMed ID: 25376708
[TBL] [Abstract][Full Text] [Related]
14. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma.
Huang J; Zheng M; Zhang Z; Tang X; Chen Y; Peng A; Peng X; Tong A; Zhou L
Cancer Immunol Immunother; 2021 Sep; 70(9):2453-2465. PubMed ID: 33543339
[TBL] [Abstract][Full Text] [Related]
17. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
[TBL] [Abstract][Full Text] [Related]
18. Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models.
Hu H; Qiu Y; Guo M; Huang Y; Fang L; Peng Z; Ji W; Xu Y; Shen S; Yan Y; Huang X; Zheng J; Su C
Oncotarget; 2015 Jan; 6(2):1079-89. PubMed ID: 25473902
[TBL] [Abstract][Full Text] [Related]
19. Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus.
Yang Y; Xu H; Huang W; Ding M; Xiao J; Yang D; Li H; Liu XY; Chu L
J Cell Mol Med; 2015 May; 19(5):915-23. PubMed ID: 25683371
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodríguez-Milla MÁ; Gil Hoyos RA; Han Y; Zhang L; Alemany R; Lesniak MS; García-Castro J
Oncotarget; 2017 Jul; 8(28):45415-45431. PubMed ID: 28525366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
